تحميل...

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to dual BRAF and MEK Inhibition in Melanoma Models

Emergence of clinical resistance to BRAF inhibitors, alone or in combination with MEK inhibitors, limits clinical responses in melanoma. Inhibiting HSP90 offers an approach to simultaneously interfere with multiple resistance mechanisms. Using the HSP90 inhibitor, AT13387, which is currently in clin...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Mol Cancer Ther
المؤلفون الرئيسيون:	Smyth, Tomoko, Paraiso, Kim H T, Hearn, Keisha, Rodriguez-Lopez, Ana M, Munck, Joanne M, Haarberg, H Eirik, Sondak, Vernon K, Thompson, Neil T, Azab, Mohammad, Lyons, John F, Smalley, Keiran S M, Wallis, Nicola G
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	2014
الموضوعات:	Article
الوصول للمادة أونلاين:	https://ncbi.nlm.nih.gov/pmc/articles/PMC4263034/ https://ncbi.nlm.nih.gov/pubmed/25349308 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-14-0452
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to dual BRAF and MEK Inhibition in Melanoma Models

مواد مشابهة